Loading clinical trials...
Loading clinical trials...
Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. During the study participants will have talks with the study staff about healthy lifestyle and physical activity. The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor. * At 6 of the visits participants will have blood samples taken. * At 5 of the visits participants will be asked to fill in a questionnaire * At 4 of the visits participants will have to do a 6-minute walking test * At 3 of the visits participants will have a test to check the heart. * participants will have their eyes checked before or at the start of the study and at the end of the study Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama, United States
Mobile Heart Specialists
Mobile, Alabama, United States
National Heart Institute Cal
Beverly Hills, California, United States
John Muir Physicians Network
Concord, California, United States
Valley Clinical Trials
Covina, California, United States
Keck Medical Center of USC - Outpatient Clinic
Los Angeles, California, United States
Valley Clinical Trials, Inc.
Northridge, California, United States
Lundquist Inst-Biomed Innovtn
Torrance, California, United States
New West Physicians,Inc.
Golden, Colorado, United States
Excel Med Ctr Clinical Trials
Boca Raton, Florida, United States
Start Date
June 15, 2021
Primary Completion Date
October 11, 2023
Completion Date
October 11, 2023
Last Updated
November 26, 2025
617
ACTUAL participants
Semaglutide
DRUG
Placebo (Semaglutide)
DRUG
Lead Sponsor
Novo Nordisk A/S
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions